Twist Bioscience Corporation Common Stock (TWST) Stock Price

TWSTStock

$151.42+392.48%52W

Market Cap$9.50B

P/E—

PEG Ratio—

Div yield—

Beta2.22

TWST Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)145.13%

Price vs S&P 500 (4W)55.95%

VGM Score64.61

Book Value / Share (Quarterly)$7.11

P/TBV (Annual)3.70x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)22.75%

Cash Flow / Share (Quarterly)$-1.57

Price vs S&P 500 (YTD)331.93%

Gross Margin (TTM)51.97%

Net Profit Margin (TTM)-31.66%

EPS (TTM)$-2.22

10-Day Avg Trading Volume1.65M

EPS Excl Extra (TTM)$-2.22

Revenue Growth (5Y)33.11%

EPS (Annual)$-1.30

ROI (Annual)-16.42%

Gross Margin (Annual)50.72%

Net Profit Margin (5Y Avg)-78.56%

Cash / Share (Quarterly)$2.66

Revenue Growth QoQ (YoY)23.24%

ROA (Last FY)-12.10%

Revenue Growth TTM (YoY)19.19%

EBITD / Share (TTM)$-1.95

ROE (5Y Avg)-29.44%

Operating Margin (TTM)-33.58%

Cash Flow / Share (Annual)$-1.25

P/B Ratio18.47x

P/B Ratio (Quarterly)14.37x

Net Income / Employee (Annual)$-79,300

EV / Revenue (TTM)18.80x

Net Interest Coverage (TTM)-235.67x

ROA (TTM)-20.80%

EPS Incl Extra (Annual)$-1.30

Current Ratio (Annual)3.64x

Quick Ratio (Quarterly)2.30x

3-Month Avg Trading Volume1.71M

52-Week Price Return392.48%

Revenue / Employee (TTM)$441,100

Tangible BV / Share (Quarterly)$6.91

P/S Ratio (Annual)21.86x

Asset Turnover (Annual)0.59x

52-Week High$145.93

Operating Margin (5Y Avg)-82.17%

EPS Excl Extra (Annual)$-1.30

CapEx CAGR (5Y)23.19%

Tangible BV CAGR (5Y)6.46%

26-Week Price Return156.37%

Quick Ratio (Annual)3.17x

13-Week Price Return139.29%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.67x

Enterprise Value$8.12B

Revenue / Share Growth (5Y)22.33%

Asset Turnover (TTM)0.66x

Book Value / Share Growth (5Y)0.91%

Revenue / Employee (Annual)$384,600

Inventory Turnover (Annual)7.08x

Pretax Margin (Annual)-20.43%

Cash / Share (Annual)$3.83

3-Month Return Std Dev88.73%

Gross Margin (5Y Avg)42.07%

Net Income / Employee (TTM)$-139,600

ROE (Last FY)-16.42%

Net Interest Coverage (Annual)-801.00x

EPS Basic Excl Extra (Annual)$-1.30

Receivables Turnover (TTM)7.13x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.22

Receivables Turnover (Annual)8.19x

ROI (TTM)-29.89%

P/S Ratio (TTM)19.07x

Pretax Margin (5Y Avg)-79.70%

Revenue / Share (Annual)$6.30

Tangible BV / Share (Annual)$7.58

Price vs S&P 500 (52W)374.17%

Year-to-Date Return343.88%

5-Day Price Return21.27%

EPS Normalized (Annual)$-1.30

ROA (5Y Avg)-23.35%

Net Profit Margin (Annual)-20.63%

Month-to-Date Return53.80%

Cash Flow / Share (TTM)$-3.08

EBITD / Share (Annual)$-1.05

Operating Margin (Annual)-23.21%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-29.42%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.22

P/TBV (Quarterly)14.80x

P/B Ratio (Annual)3.59x

Inventory Turnover (TTM)6.79x

Pretax Margin (TTM)-31.46%

Book Value / Share (Annual)$7.80

Price vs S&P 500 (13W)136.50%

Beta2.22x

Revenue / Share (TTM)$6.92

ROE (TTM)-29.89%

52-Week Low$23.30

vGradeD

gGradeB

mGradeA

vgmGradeB

TWST Earnings Surprise History

Q2 25-0.47est. -0.57

Q3 25-0.45est. -0.50

Q4 25-0.50est. -0.52

Q1 26-0.60est. -0.53

Q2 26-0.56est. -0.18

TWST Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.31

4.47

4.38

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About Twist Bioscience Corporation Common Stock

Twist Bioscience Corp develops a semiconductor-based DNA synthesis platform that manufactures synthetic DNA on silicon, enabling faster production and lower costs than traditional methods. This proprietary technology supports high-throughput, cost-effective synthesis and accelerates innovation across research and development. The company generates revenue from three geographic regions—Americas, EMEA, and APAC—with the majority coming from North America.